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Mobile health apps are health and wellness programs available on mobile devices such as smartphones or tablets.
In three systematic assessments published in BMC Medicine, Huckvale and colleagues demonstrate that widely
available health apps meant to help patients calculate their appropriate insulin dosage, educate themselves about
asthma, or perform other important functions are methodologically weak. Insulin dose calculators lacked user input
validation and made inappropriate dose recommendations, with a lack of documentation throughout. Since 2011,
asthma apps have become more interactive, but have not improved in quality; peak flow calculators have the same
issues as the insulin calculators. A review of the accredited National Health Service Health Apps Library found poor
and inconsistent implementation of privacy and security, with 28 % of apps lacking a privacy policy and one even
transmitting personally identifying data the policy claimed would be anonymous. Ensuring patient safety might require
a new approach, whether that be a consumer education program at one extreme or government regulation at the
other. App store owners could ensure transparency of algorithms (whiteboxing), data sharing, and data quality. While a
proper balance must be struck between innovation and caution, patient safety must be paramount.
Please see related articles: http://dx.doi.org/10.1186/s12916-015-0444-y, http://www.biomedcentral.com/1741-7015/13/106
and http://www.biomedcentral.com/1741-7015/13/58
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Mobile health apps are software tools that can help users
manage their health through a smartphone or tablet,
ranging from simple diaries or reminders to more com-
plex programs certified by health authorities as medical
devices. The potential for mobile health apps is undoubt-
edly great, with half a billion users already [1]. However,
three linked studies published in BMC Medicine question
the safety and quality of medical apps in today’s lightly
regulated market. Huckvale and colleagues conducted sys-
tematic assessments of smartphone apps for calculating
insulin dosage [2], educating patients about asthma [3],
and the privacy characteristics of “accredited” apps in the
National Health Service (NHS) Health Apps Library [4].
Their findings make for sobering reading.
Insulin dose calculation is a basic task, for which we
might reasonably assume we can trust a computer better
than our human faculties. However, assessment of apps* Correspondence: pwicks@patientslikeme.com
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force us to consider critically the current ecosystem [2].
It is alarming to read that 91 % of dose calculators lack
validation to check the data quality of user input and
67 % risked making an inappropriate dose recommenda-
tion. There was a disappointing lack of transparency too,
with 70 % lacking documentation for the formula used,
46 % of developers failing to respond to requests for in-
formation, and two developers flat-out refusing to share
their algorithm with researchers, citing commercial rea-
sons. Quality was no higher for paid apps than free ones,
and no higher in the Apple store than the Android store,
despite Apple having more stringent entry criteria for
apps in general. Most errors pointed patients toward
taking a higher dose of insulin than was needed, with
the potential for avoidable hypoglycemia.
A review of self-management education apps for
asthma, also by Huckvale et al., scored apps on their de-
gree of conformity with evidence-based guidelines in
areas such as inhaler technique. The most recent studys article is distributed under the terms of the Creative Commons Attribution 4.0
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view from 2011 [5] found a number of cosmetic up-
grades intended to boost user engagement, such as
multimedia content, social networking, gamification,
sensor integration, and cloud data storage, but sadly
with no improvement in the actual quality of content . A
third (33 %) lacked correct information about inhaler
preparation and mouth positioning, and only half cor-
rectly described the proper sequence of inhalation. Peak
flow calculators, which provide a measure of how well
lungs are functioning, had similar shortcomings to the
insulin dose calculators in nine of the apps assessed.
Finally, a third study describes a systematic security
and privacy review of apps in the accredited NHS Health
Apps Library, a space in which consumers might reason-
ably assume that such issues would be robustly ad-
dressed [4]. However here, too, the authors found
inconsistency and poor discipline, with apps storing
medical data in ways that left them susceptible to inter-
ception or data leaking, as well as highly variable uses of
privacy policies. In one case, an app was found to trans-
mit a form of data explicitly claimed not to be transmit-
ted in its privacy policy.Health apps are consistently poor in quality
While the authors’ first two studies focused on diabetes
and asthma, poor results have been reported in other fields
too. For example, a dermatology app claiming to have been
downloaded over 35,000 times purported to identify pre-
cancerous moles. However, on testing it was found to have
just 10 % sensitivity to classify biopsy-proven melanomas
correctly [6]. A highly downloaded rheumatology app fea-
turing various calculators was withdrawn for giving users
15–20 % inaccurately higher scores on a disease activity
score (DAS28 [7]) for one formula and a 10–15 % lower
score than was accurate for another [8].
In order for medical apps to evolve, improved over-
sight and continuous quality review is required. Central-
ized oversight by regulatory bodies has the advantage of
regulatory expertise and powers to sanction. However,
these regulatory bodies are too under-resourced to wade
through the sheer volume of apps and there appears to
be little appetite to get involved.
Although there are many apps that purport to help
with health, in the USA, the Food and Drugs Adminis-
tration (FDA) will only intervene should an app be
found disreputable, and perhaps not even then [9]. Vol-
untary certification schemes such as the Happtique
Health App Certification Program have been piloted
[10]. Despite best intentions, however, this program was
wound down after only 2 years because a random selec-
tion of “certified” apps chosen for review contained
major security flaws [11].In the UK, the NHS Health Apps Library requires de-
velopers to complete a structured series of questions
about security, quality, and privacy to be reviewed by an
internal team. However, in the third linked study by
Huckvale et al. [4] the authors found a number of flaws
regarding privacy in accredited apps. Moreover, most pa-
tients access apps through native stores rather than
accredited portals, further highlighting the importance
of wariness when it comes to security and privacy issues.
In an accredited environment, the speed and revision of
review is an important factor when review processes take
months or years, while apps can be updated in a matter
of weeks and hardware changes regularly [11].
An alternative might be for developers to self-certify ac-
cording to a checklist in order to reassure the public and
maintain their own quality assurance. However, systematic
self-certification [12] or a systematic rating scale [13] do
not bring more observers to the table but rather rely on
the developers’ honesty and competence; there are also
few benefits and no sanctions to drive compliance. Peer
reviews are offered by journals (e.g., JMIR mHealth and
uHealth) and commercial sites (e.g., iMedicalApps), but
such reviews are few and far between relative to the high
number and evolving landscape of health apps. Al-
though important for user satisfaction, rating app
quality primarily on dimensions such as visual appeal,
functionality, and overall satisfaction without rigorous
data quality checking [13] fails to put sufficient em-
phasis on uncovering the type of data quality issues
identified in the studies described here.
Some proposed approaches to improvement
What would an ideal process look like? Unlike pills or
medical devices, there are few centralized gatekeepers
between app developers and end-users, no systematic
surveillance of harms, and little power for enforcement.
Here, we consider five possible approaches that could be
taken (Table 1).
Boost app literacy
The most light-touch approach would be a bottom-up
strategy to educate consumers about how to evaluate
and interpret their own data in health apps [11]. App de-
velopers could voluntarily choose to increase transpar-
ency through prominent placement of documentation in
the app store that highlights the testing, reliability/valid-
ity, data privacy policies, and business model of their
medical app. This information could include lay descrip-
tions of the populations(s) on which the app was tested,
the context of testing, the validity and reliability of the
data collected by the app, and how the app developer
will make money or otherwise fund future improve-
ments in the app. Consumers could then place greater
faith in what they read if developers have submitted
Table 1 Five potential approaches to improving the quality of medical apps
Approach Who leads the approach? Emphasis of approach Strengths Weaknesses
Boost app literacy The medical technology
community
Educate consumers






on patients, no oversight
or enforcement







Low yield, no current
infrastructure, funding
Enforced transparency App Stores and Researchers Enable external validation
by third parties
Continuous quality assessment,
enforceable by app stores
Threat to competitiveness,
additional work for developers
Active medical review App Stores Medical review of every app
before release to the public
Robust, enforceable,
drives quality and safety
Barrier to innovation,
reduces number and
diversity of apps, costly, slow




Medical review of every app
before release to the public
Existing powers, enforceable,
drives quality and safety
Very slow, cost borne
by government, barrier
to innovation
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proval. The information provided might also improve a
user’s health literacy by highlighting important aspects
of the app that they should consider before installation.
The challenge to this approach is that even a trained
clinician might struggle to access all the relevant litera-
ture and systematically assess every version of every app
in every permutation of user, much less understand
complex security and privacy issues and synthesize them
to make a rational decision—most patients could also
find this extremely challenging.
App safety consortium
Given the need for multiple stakeholders to tackle the
problem but bearing in mind the view of developers who
would resist active control, a second approach would be
to convene an app safety consortium of developers,
safety researchers, patient advocates, and regulators,
which might investigate systems for consumer reporting
of adverse events resulting from app use, such as insulin
overdose, an approach that has been proposed for
patient-reported outcomes in clinical trials of drugs and
medical devices [14]. Properly elucidating the level of
harm arising from poor app design might draw greater
scrutiny, encourage the sharing of best practices, or, while
rarely the desired mechanism, encourage litigation that
sharpens focus on addressing these issues robustly. Such a
consortium would serve as an organizing force to further
develop regulatory and risk management frameworks.
Enforced transparency
A third approach would be for the owners of the app
stores to enforce the ability to evaluate medical calcula-
tor apps transparently in the same way that Clinical-
Trials.gov permits external third parties to look for
deviations in protocols, changes in statistical planning,or lack of publication [15] without manually reviewing
every trial themselves. In order to access their popula-
tion of consumers, app developers would be required to
submit documentation (viewable by all and accessible
through an open database) to be reviewed by anyone but
particularly amenable to review by consortia of re-
searchers and clinicians who could evaluate relevant as-
pects of each app with automated software. This would
effectively be “whiteboxing” what was previously a “black
box” and allow third parties to develop software that
checks the functioning of apps as a service to devel-
opers, app store owners, clinicians, and the public. The
degree of transparency enforced may require tweaking
to ensure the competitive advantage is not eliminated
for those developers who have done the hard work to
ensure the quality of their product.
Active medical review
A more active approach would be that those running
app stores, such as Apple and Google, take full responsi-
bility for every aspect of security and quality for medical
apps as a “benign dictatorship.” After withdrawing all
current medical apps in their app stores (which we know
from these studies include under-developed programs
created by amateurs with no intention of providing on-
going support), they would need to implement a robust
testing program staffed by clinicians, security experts,
and quality assurance software engineers who would
thoroughly vet medical apps before they were released
to the public. While this most conservative approach
might sound appealing to clinicians and safety enthusi-
asts, it is also the least likely to succeed.
For instance, Apple already has a complex set of App
guidelines in place [16], although as one commentator
claims, “the rules are subjective and poorly enforced”
[17]. Apps already take a substantial amount of time and
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complex verification steps that would be required to
remedy some of the issues described by Huckvale and
colleagues, and because health apps probably account
for a very small proportion of revenue, it would be hard
to imagine technology companies taking on the adminis-
trative burden as well as the potential for liability should
harms arise from apps that have undergone a more
rigorous review.
Government regulation
Any of these approaches is probably still preferable to the
final extreme: government regulation of smartphone apps.
Only a tiny number of health apps, such as OncoAssist,
have gone through European Union Kitemark certification
to be qualified as a medical device, a rigorous process that
ensures the data they present can be relied upon for clin-
ical decision-making [10]. If the public wanted to be more
confident of safety and app store owners did not want to
hire a brigade of technologically minded clinicians to re-
view each app, governments could decide to increase the
resources available to the existing regulatory bodies to en-
hance their capabilities and increase the throughput of
testing programs. However, this approach likely carries
more burden than opportunities.
Conclusion
Any one of these approaches will add complications and
cost to the simple act of downloading an app, but this
may still be preferable to avoidable serious adverse
events inflicted by software bugs or sloppy practice. Do
we want 100,000 medical apps, most of which are
shoddy? Or do we want 1,000 that we can rely upon? It
is the patients, their caregivers, and their healthcare pro-
fessionals who should drive what an appropriate level of
rigor might be, and ultimately they are the only ones
who can exert pressure to change the system. We believe
most people would be surprised at the low standards of
apps described by these three important studies and dis-
appointed that the safeguards they rely upon in other
spheres of life, such as truth in advertising, professional
practice standards, or clinical testing of medical prod-
ucts, appear to be absent in this exciting and much-
hyped area of techno-utopianism. In considering
whether a bottom-up or top-down approach is best, we
must also balance innovation and diversity of approaches
against patient wellbeing—there is no point “disrupting”
the established healthcare system if the new era is not
safer for patients than the old one.
As medical innovators, this has been a difficult set of
data to fathom. We eagerly look forward to a time when
medical apps might be relied upon to do much more
complex tasks than simply calculate formulae or illus-
trate inhaler technique; for example, recommendingpersonalized dosage schedules, analyzing patterns in user
behavior, interacting with the Internet of Things, per-
haps even controlling implanted medical devices. The
potential for benefit remains vast and the degree of
innovation is inspiring, but it turns out we are much
earlier in the maturation phase of medical apps than
many of us would have liked to believe. To build the fu-
ture we want, in which patients can trust their medical
apps, we need to verify that they function as intended.
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